As the Biden administration leans into the Cancer Moonshot 2.0, the life sciences industry has the opportunity to launch a new era of precision oncology. How can we accelerate progress toward truly personalized medicine and revolutionize cancer care?
Overheard at the J.P. Morgan Healthcare Conference
Executives detailed plans to take on more risk, build on advances in life sciences, and expressed optimism in Medicare Advantage, despite missing enrollment targets.
And How Stakeholders Can, Literally, Save the World
Climate change will be the biggest impact on global health. The healthcare industry may not respond in time.
Social distancing may be necessary for two years or more. Here's where remote care comes into play.
In our rearview mirror is a ten-year stretch of experimentation. What looms ahead is the rewriting of healthcare's rules.
A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.
Our most popular articles of the year offered our predictions on disruption and the future market, and highlighted our views on healthcare reform, ACOs, and much more.
Purposeful collaboration will help more people understand how their daily decisions dictate their health.
Advice on how the healthcare industry can address the pharmaceutical cost problem.
In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.